Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session -Gastrointestinal, non-colorectal

5302 - Preliminary Results of a Ph2a Study to Evaluate the Clinical Efficacy and Safety of Erdafitinib in Asian Patients with Biomarker-Selected Advanced Cholangiocarcinoma (CCA)

Date

19 Oct 2018

Session

Poster Discussion session -Gastrointestinal, non-colorectal

Presenters

Yen-Yang Chen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

Y. Chen1, J.O. Park2, W. Su3, D. Oh4, K. Kim5, Y. Feng6, L. Shen7, H. Liao8, J. Nie9, M. Qing10, J. Li11, P. De Porre12

Author affiliations

  • 1 Department Of Haemato-oncology, Chang Gung Memorial Hospital-Kaohsiung, 833 - Kaohsiung/TW
  • 2 Division Of Hematology-oncology, Department Of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 3 Department Of Internal Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan/TW
  • 4 Department Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 5 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 6 Division Of Hematology And Oncology , Chi-Mei Medical Center, 710 - Tainan/TW
  • 7 .department Of Gi Oncology, Peking University Cancer Hospital & Institute, Beijing/CN
  • 8 Statistics & Decision Sciences, Janssen China R & D Center, Shanghai/CN
  • 9 Clinical Pharmacology, Janssen China R & D Center, Beijing/CN
  • 10 Department Of Biomarker, Janssen China R & D Center, Shanghai/CN
  • 11 Early Development, Janssen China R & D Center, Shanghai/CN
  • 12 Be Clinical Oncology, Janssen R&D BE, Beerse/BE
More

Resources

Abstract 5302

Background

Advanced CCA patients (pts) who progressed after first-line chemotherapy have limited treatment options and poor prognosis. Aberrant fibroblast growth factor receptor (FGFR) signalling is a driver of the pathogenesis of CCA and is observed in 14-17% of pts. Erdafitinib, a potent oral pan-FGFR tyrosine kinase inhibitor, demonstrated encouraging clinical activity with manageable adverse events (AEs) in the Europe (EU)/United States (US) phase 1 study in solid tumours, including subjects with CCA.

Methods

LUC2001 is an open-label, multicenter, Ph2a study in advanced CCA pts with FGFR alterations, based on FoundationOne testing, who failed at least 1 prior systemic treatment. The primary endpoint is objective response rate (ORR; by RECIST 1.1). The secondary endpoints are disease control rate (DCR), safety and pharmacokinetics. Disease is evaluated every 8 weeks until disease progression (PD).

Results

As of 20 March 2018, 150 CCA pts are molecularly screened; 25 have FGFR alterations, of whom 11 (with FGFR2 fusions [7] or FGFR 2 [2] or 3 [2] mutations) are dosed with continuous 8 mg once daily erdafitinib, all response evaluable. Median age is 53.0 years, ECOG score 0 and 1 in 6 and 5 pts, respectively, 8 males and 3 females. Median number of treatment cycles is 4.0 and median treatment duration is 3.5 months. There are 3 confirmed partial response (PR), 2 unconfirmed PR (uPR), 4 stable disease (SD), and 2 PD (both with FGFR3 mutations). The ORR (CR+PR+uCR+uPR) is 45.5%. The DCR (CR+PR+uCR+uPR+SD) is 81.8%. Six pts are still on treatment. The most common AEs (>30%) are hyperphosphatemia, dry mouth, stomatitis, diarrhea, nail disorder, and palmar-plantar erythrodysaesthesia syndrome. Seven pts experienced Grade 3 or higher AEs and 3 subjects had AEs leading to dose reduction. Three pts experienced non-drug related serious AEs (SAEs), while no AE led to treatment discontinuation or death. PK characteristics are consistent with data from other studies.

Conclusions

Erdafitinib shows encouraging clinical activity and tolerable safety profile in Asian and EU/US pts with FGFR-altered advanced CCA with high unmet medical need.

Clinical trial identification

NCT02699606.

Legal entity responsible for the study

Janssen (China) Research & Development Center, a division of Johnson & Johnson (China) Investment Ltd.

Funding

Janssen APMS China Research & Development.

Editorial Acknowledgement

Disclosure

H. Liao, J. Nie, M. Qing, J. Li, P. De Porre: Employee: Janssen Research and Development; Stock ownership: Johnson&Johnson. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.